Skip to main content
. 2016 Dec 6;312(3):H415–H421. doi: 10.1152/ajpheart.00645.2016

Table 3.

Univariable and multivariable linear regression analyses of sulfate clearance and clinical parameters in CHF

Univariable Regression for Sulfate Clearance
Multivariable Regression for Sulfate Clearance
Coefficient P value Coefficient P value
Characteristics
    Age −0.545 <0.001‡
    Male −11.354 0.066
    Current smoker −0.975 0.710
    BMI 0.141 0.703
    Systolic blood pressure 0.035 0.713
    Diastolic blood pressure 0.275 0.079
    Heart rate 0.188 0.281
Heart failure history
    Duration HF* −0.793 0.649
    Ischemic etiology −2.542 0.475
    NYHA class II/III −14.112 0.005‡
    LVEF −0.040 0.838
Treatment
    β-Blocker 10.838 0.243
    MRA −5.285 0.136
    Diuretic −9.389 0.003‡ −4.322 0.048‡
Laboratory measurements
    NT-proBNP* −6.689 <0.001‡
    Serum albumin 1.877 0.004‡
    Total serum protein −0.651 0.117
    Creatinine clearance 0.369 <0.001‡ 0.331 <0.001‡
    24-h Urinary albumin 0.046 0.098
    24-h Urinary sodium 0.177 <0.001‡ 0.077 0.023‡
    HbA1C 2.422 0.356
    Cholesterol 1.547 0.315
    HDL −7.268 0.088
    LDL 1.930 0.271
    Calcium −21.940 0.257
    PTH −0.446 0.270
    PRC* −1.640 0.086
    PRA* −1.623 0.060
    Aldosterone* −4.281 0.032‡
    1,25(OH)2D 0.046 0.207

CHF, chronic heart failure; BMI; body mass index; HF, heart failure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid-receptor antagonists; NT-proBNP; NH2-terminal pro-B-type natriuretic peptide; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PTH, parathyroid hormone; PRC, plasma renin concentration; PRA, plasma renin activity.

*

Skewed data, normalized by logarithmic transformation. ‡Significant P value.